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Background: Pulmonary sarcoidosis is frequently characterized by a CD4þ/CD8þ ratio 3.5 in
bronchoalveolar lavage fluid (BALF), although up to 40% of the cases present a normal or even
decreased ratio, pointing out its variability and limitation as a diagnostic marker for sarcoid-
osis. Lung lymphocytes within the bronchial epithelium, the alveolar walls, and BALF express
the integrin CD103. Our aim was to compare the expression of CD103 in BALF T-lymphocytes
between sarcoidosis and other interstitial lung diseases (ILD) and to evaluate its relevance
as a BALF diagnostic marker for sarcoidosis.
Methods: A total of 86 patients with ILD (mean age  standard deviation, 42.6  16.6 years;
60.5% female), who underwent BALF as part of their initial diagnostic work-up, were enrolled
into 2 groups: sarcoidosis (n Z 41) and other ILD (n Z 45). Area under the receiver operating
characteristic (ROC) curve (AUC) was used to describe the performance of CD103 for sarcoid-
osis diagnosis.
Results: Sarcoidosis patients presented a significantly reduced CD103 expression in BALF T-
lymphocytes, more pronounced in the CD4þ subset. The BALF CD103þCD4þ/CD4þ ratio for
a cutoff point of 0.45 was associated with a better diagnostic performance for sarcoidosis
(AUC: 0.86 [95% confidence interval (95% CI): 0.78e0.94]; sensitivity: 81%; specificity: 78%),
even for those with a CD4þ/CD8þ ratio <3.5 (AUC: 0.79 [95% CI: 0.64e0.93]; sensitivity:
75%; specificity: 78%).e Medicina da Universidade do Porto, Alameda Professor Hernaˆni Monteiro, 4200-319 Porto, Portugal.
5512214.
.com (A. Morais).
2 Elsevier Ltd. All rights reserved.
CD103 expression in sarcoidosis 1015Conclusions: Assessment of CD103 expression in BALF CD4þ T-lymphocytes may be a reliable
tool for sarcoidosis diagnosis, independently of CD4þ/CD8þ ratio, pointing out the relevance
of evaluating the CD103þCD4þ/CD4þ ratio in the ILD diagnostic work-up.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Sarcoidosis is the most common interstitial lung disease
(ILD) in western world, with an estimated prevalence of
10e20 per 100,000 people.1,2 It is a multisystem inflam-
matory disorder of unknown origin that commonly affects
young adults. It is characterized by the accumulation of
macrophages and CD4þ T-lymphocytes in involved organs,
with non-caseating granuloma formation, being the lungs,
lymph nodes and skin the most frequently affected.3,4
The diagnosis of pulmonary sarcoidosis encloses
a correct clinical setting, typical chest radiographic or high-
resolution computed tomography (HRCT) features and
a biopsy showing non-caseating granulomas.3,5e7 Bron-
choalveolar lavage fluid (BALF) is considered as a standard
procedure in the diagnostic work-up of patients with ILD. In
sarcoidosis the value of the BALF CD4þ/CD8þ ratio to
differentiate it from other ILD has been examined by
several authors, which conclude that in patients with
a typical clinical picture an elevated BALF CD4þ/CD8þ ratio
may support the diagnosis of sarcoidosis and obviate the
need for confirmation by additional biopsy.810 Those
studies demonstrated that a CD4þ/CD8þ ratio greater than
3.5 shows a high specificity of 93e96% for sarcoidosis,
although the sensitivity is low, approximately
52e59%.8,9,11,12 On the other hand, other studies13 question
the clinical usefulness of the BALF CD4þ/CD8þ ratio, based
on the observation that this ratio is highly variable. These
authors found that only 42% of 86 patients with biopsy-
proven sarcoidosis had a BALF ratio greater than 4.0, and
that 12% had even an inverted ratio below 1.0, reflecting
a predominance of CD8þ T-lymphocytes.
Consequently, there has been a great interest in the
investigation of other cellular markers with a reliable
diagnostic accuracy for sarcoidosis. In this context, the
expression of CD103 (integrin aEb7) in BALF CD4
þ lympho-
cytes has been shown to be a promising candidate.14
Terminally differentiated mucosal intraepithelial T-
lymphocytes express the integrin aEb7, an adhesion mole-
cule and homing receptor that binds to E-cadherin,
a molecule vital for the adhesion and retention of epithelial
cells.15 In the lung, lymphocytes within the bronchial
epithelium, the alveolar walls, and BALF express the
integrin CD103,16,17 although with a variable magnitude of
expression.18 In fact, a great variation of the CD103
expression in BALF CD4þ and CD8þ T-cells has been repor-
ted in ILD, suggesting a possible role of these subpopula-
tions in the pathogenesis and differential diagnosis of some
of these disorders.19 Kolopp-Sarda et al. found that
sarcoidosis was remarkably characterized by the lack of
CD103 expression in the predominant CD4þ subset.14 The
peripheral origin of CD4þ BALF lymphocytes in sarcoidosis
seems to be responsible for its lower expression of CD103.14These observations may be relevant for the diagnosis of
sarcoidosis, namely through the analysis of CD103þCD4þ
cell expression, along with the BALF CD4þ/CD8þ and even
BALF/peripheral blood ratios.14,20
Thus, we aimed to compare the expression of CD103 in
BALF T-lymphocytes between patients with diagnosis of
sarcoidosis and other ILD, and to evaluate its relevance as
a BALF diagnostic marker for sarcoidosis.Methods
Study population
A total of 86 patients with a confirmed ILD diagnosis (mean
age  standard deviation, 42.6  16.6 years; 60.5%
female), who underwent BALF as part of their initial diag-
nostic work-up, were enrolled in the study. Patients were
divided into 2 groups for comparison effects, namely
sarcoidosis (n Z 41) and other ILD (n Z 45).
Sarcoidosis diagnosis was based on a multimodality
approach that combined clinical, radiological, and histo-
logical evaluation showing non-caseating granulomas,
according to the American Thoracic Society/European
Respiratory Society/World Association for Sarcoidosis and
Other Granulomatous Disorders (ATS/ERS/WASOG) state-
ment.5 This diagnosis was also considered in those
with clinical and radiological features typical of sarcoid-
osis associated with a BALF CD4þ/CD8þ lymphocyte ratio
3.5. Chest radiographic staging was performed for all
sarcoidosis patients according to Scadding criteria: stage
0 e normal (n Z 1), stage I e mediastinal and bilateral
hilar lymphadenopathy without lung involvement
(n Z 14), stage II e lymphadenopathy and lung involve-
ment (n Z 21), stage III e only lung involvement (n Z 0),
stage IV e lung fibrosis (n Z 5).5,21 A group of 22 patients
had a diagnosis of hypersensitivity pneumonitis (HP),
according to Schuyler et al.’s criteria.22 The diagnosis of
idiopathic interstitial pneumonia was based on surgical
lung biopsy features or in accordance to the ATS/ERS
International Multidisciplinary Consensus Classification of
the Idiopathic Interstitial Pneumonias: idiopathic pulmo-
nary fibrosis (IPF) (n Z 4); non-specific interstitial pneu-
monia (NSIP) (n Z 3); cryptogenic organizing pneumonia
(COP) (nZ 1).23 Connective tissue disease-associated lung
disorders were diagnosed according to international
proposed criteria associated with HRCT scan and BALF
features: systemic lupus erythematosus (SLE) (n Z 3);
rheumathoid arthritis (n Z 3); scleroderma (n Z 2).2426
Drug-induced lung disease (3 by rapamycin and 1 by
capecitabine) and silicosis (nZ 3) diagnosis were based on
a compatible exposure history, radiological and BALF
features.27,28
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Bronchoalveolar lavage and flow cytometry
BAL was performed according to the ERS recommenda-
tions,29 by flexible bronchoscopy at the time of diagnosis.
Briefly, four aliquots of 50 mL sterile isotonic saline solution
(37 C) were instilled under fiberoptic bronchoscopy in the
middle lobe and gently aspirated with a syringe (after each
instillation). Recovered BALF was pooled (discarding the
first aliquot), gauze filtered and the total cell numbers
(Neubauer chamber) determined. Cell differentials were
obtained by counting 500 cells on cytospin preparations
stained with Wright-Giemsa. For phenotypic analysis, cells
were centrifuged at 250 G for 10 min, washed twice,
resuspended, and labeled with the following combination
of monoclonal antibodies: anti-CD103-FITC, anti-CD8-Pe,
anti-CD45-PercP-Cy.5 and anti-CD4-APC (Becton Dickinson
Immunocytometry Systems, BDIS, San Jose´, CA, USA). CD3,
CD19, and CD56 expressions were also assessed in a parallel
sample. Cells were acquired on a FACScan Flow Cytometer,
using CellQuestPro Software (Beckton and Dickinson, BD
Biosciences, San Jose´, USA). Lymphocyte gating was based
on forward scatter (FSC) versus side scatter (SSC). Addi-
tional gating was based on SSC versus CD45, CD4 and CD8
populations. BALF CD4þ, CD8þ, CD103þCD4þ and
CD103þCD8þ T-lymphocytes were analyzed.
Statistical analysis
Data were described as mean and standard deviation or as
median and interquartile range (IQR) for quantitative
variables, and as counts and proportions. For comparison
of quantitative variables the Student’s t-test and the
ManneWhitney test were used according to variables
distribution.
Sensitivity and specificity were calculated for a set of
cutoff points of the various calculated forms of CD103
expression in BALF CD4þ and CD8þ T-lymphocytes.
The area under the receiver operating characteristic (ROC)
curve (AUC), which plots sensitivity against 1 e specificity,Table 1 Comparative analysis of T-lymphocyte subpopulations a
other interstitial lung disease (ILD).
Sarcoidosis (n Z 41)
Lymphocytes (%) 34.8 (30.5)
CD4þ (%) 79.4 (15.7)
CD8þ (%) 14.8 (11.7)
CD4þ/CD8þ 5.7 (5.1)
CD103þCD4þ (cells/mL) 5411 (19,179)
CD103þCD4þ (%) 11.9 (14.5)
CD103þCD4þ/CD4þ 0.20 (0.25)
CD103þCD8þ (cells/mL) 2441 (6923.5)
CD103þCD8þ (%) 27.3 (46.6)
CD103þCD8þ/CD8þ 2.00 (2.35)
CD103þCD4þ/CD103þCD8þ 0.50 (0.60)
Quantitative variables are expressed as median and interquartile ranwas used to describe the diagnostic performance of those
variables. Positive and negative predictive values (PPV and
NPV) were also estimated.
Statistical analyses were performed using the Statistical
Package for Social Sciences for Windows version 18 (SPSS;
Chicago, IL, USA). Statistical significance was denoted by
a p-value lower than 0.05 for all tests performed.
Results
Expression of CD103 in BALF T-lymphocytes
A significantly higher CD4þ/CD8þ ratio in BALF was found
for sarcoidosis patients compared to patients with other ILD
(Table 1). The comparative analysis of the CD103 expres-
sion in the CD4þ and CD8þ T-lymphocyte subpopulations
(CD103þCD4þ cells/mL; CD103þCD4þ %; CD103þCD4þ/CD4þ;
CD103þCD8þ cells/mL; CD103þCD8þ %; CD103þCD8þ/CD8þ;
CD103þCD4þ/CD103þCD8þ) between both groups (sarcoid-
osis versus other ILD) is represented in Table 1. As expec-
ted, in the sarcoidosis group, the absolute counts and
percentages were significantly lower compared to the other
group. Moreover, CD103 expression in the CD4þ T-lympho-
cyte subset was lower than CD103 in CD8þ T-cells.
As compared to other ILD, BALF CD103þCD4þ/CD4þ
ratio, reflecting the relative number of CD4þ T-lymphocytes
that express CD103 within the total CD4þ subpopulation,
was also lower e 0.20 (IQR 0.25) versus 1.00 (IQR 1.50),
p < 0.001 e in sarcoidosis patients (Table 1). This ratio was
significantly higher in more advanced radiographic stages
(stages 1: 0.10 (IQR 0.10) versus stages 2: 0.20 (IQR
0.43); p Z 0.044).
Diagnostic criteria of BALF CD103 expression
(sensitivity, specificity, cutoff levels)
Sets of cutoff points were established for the different
values of CD103 expression in BALF T-lymphocytes, calcu-
lating their respective sensitivity and specificity values for
sarcoidosis diagnosis (data available as supplementary
material e Annexes 1 and 2). In accordance, and for
the same cutoff 0.25, BALF CD103þCD4þ/CD4þ andnd CD103þ expression between patients with sarcoidosis and
Other ILD (n Z 45) p-value
53.0 (43.7) 0.014
38.0 (35.5) <0.001
46.4 (33.1) <0.001
0.9 (1.3) <0.001
11,185 (43,215) 0.024
32.6 (44.2) <0.001
1.00 (1.50) <0.001
42,646 (147357.5) <0.001
64.0 (55.6) <0.001
1.2 (1.45) 0.018
0.60 (0.50) 0.199
ge (IQR).
Table 2 Sensitivity (Sn) and specificity (Sp) of the BALF CD103þCD4þ/CD4þ ratio for sarcoidosis diagnosis in the study pop-
ulation (left column), and in a subgroup of sarcoidosis with a BALF CD4/CD8 <3.5 (right column) all with histological confir-
mation, comparatively with the other ILD.
All sarcoidosis patients (n Z 41) Sarcoidosis with BALF CD4þ/CD8þ <3.5 (n Z 12)
CD103þCD4þ/CD4þ Sn (%) Sp (%) CD103þCD4þ/CD4þ Sn (%) Sp (%)
0.05 12 100 0.15 25 93
0.15 42 93 0.25 42 91
0.25 63 91 0.35 58 80
0.35 76 80 0.45 75 78
0.45 81 78 0.55 75 71
0.55 83 71 0.65 83 64
0.65 88 64 0.75 83 60
0.75 88 60 0.85 83 56
0.85 90 56 0.95 83 53
0.95 93 53 1.05 83 49
Sn, sensitivity; Sp, Specificity.
CD103 expression in sarcoidosis 1017CD103þCD4þ/CD103þCD8þ ratios were highly specific for
sarcoidosis (specificity >90% for both), but with a low
effect in sensitivity values (sensitivity for CD103þCD4þ/
CD4þ <63% and for CD103þCD4þ/CD103þ CD8þ <20%)
(Table 2 and Annex 1).
ROC curves were performed in order to better evaluate
the diagnostic value of CD103 BALF expression in sarcoidosis
and to determine the cutoff values with the best sensibility
and specificity relationship. Among the aforementioned
variables, the CD103þCD4þ/CD4þ ratio, for a cutoff point of
0.45, was associated with a better diagnostic performance
(sensitivity: 81%; specificity: 78%; PPV: 77%; NPV: 81%)
(Table 3), as shown by ROC curves (Fig. 1a) and respective
AUC (AUC: 0.86 [95% CI: 0.78e0.94]). In comparison,
CD103þCD4þ/CD103þCD8þ ratio, for the same cutoff value
(0.45), despite a similar specificity, had a low sensitivity for
sarcoidosis and consequently a lower AUC (sensitivity: 44%;
specificity: 73%; PPV: 60%; NPV: 59%; AUC: 0.58 [95% CI:
0.46e0.70]) (Table 3 and Fig. 1c).
CD103 expression in sarcoidosis patients with BALF
CD4D/CD8D ratio<3.5
Among the 41 sarcoidosis patients included, 12 (29.3%)
presented a BALF CD4þ/CD8þ <3.5 but with histologicalTable 3 Cutoff values, sensitivity (Sn), specificity (Sp), positive
different bronchoalveolar lavage fluid (BALF) criteria evaluated f
Criteria Selected cutoff Sn (%)
CD103þCD4þ (cells/mL) 7286 59
CD103þCD4þ (%) 17.85 71
CD103þCD4þ/CD4þ 0.45 81
CD103þCD8þ (cells/mL) 19,954 98
CD103þCD8þ (%) 46.9 71
CD103þCD8þ/CD8þ 1.35 71
CD103þCD4þ/CD103þCD8þ 0.45 44
Sn, sensitivity; Sp, specificity; PPV, positive predictive value; NPV, n
interval.evaluation showing non-caseating granulomas. Similar
statistical analysis was performed for this subgroup. In
comparison with the others parameters, the CD103þCD4þ/
CD4þ ratio (for the same cutoff point, 0.45, determined for
the overall sarcoidosis group) revealed the best diagnostic
performance, as shown by AUC magnitude (sensitivity: 75%;
specificity: 78%; PPV: 47%; NPV: 92%; AUC: 0.79 [95% CI:
0.64e0.93]) (Table 4 and Fig. 1b).Discussion
Sarcoidosis is characterized by an alveolar CD4þ lympho-
cytosis, the effector cells involved in the T-helper 1
immune response, and consequently a high BALF CD4þ/
CD8þ ratio.3,4,8e10 Although with a high specificity, an
elevated CD4þ/CD8þ ratio does not fully discriminate
sarcoidosis from other ILD.13 CD4þ lymphocytosis may also
be observed in other types of lung diseases,30 and the
sensitivity for sarcoidosis of an elevated CD4þ/CD8þ ratio is
seldom more than 50% in the studies available in litera-
ture.8,9,11 Additionally, difficulties also rise in those cases
of sarcoidosis with a normal or inverted CD4þ/CD8þ ratio.
Thus, other BALF cellular markers that may help in
sarcoidosis differential diagnosis have been searched.predictive value (PPV) and negative predictive value (NPV) for
or sarcoidosis diagnosis.
Sp (%) PPV (%) NPV (%) AUC (CI 95%)
69 63 65 0.64 (0.53e0.76)
80 76 75 0.75 (0.66e0.87)
78 77 81 0.86 (0.78e0.94)
62 70 97 0.84 (0.76e0.93)
69 67 72 0.72 (0.61e0.83)
60 62 69 0.65 (0.53e0.77)
73 60 59 0.58 (0.46e0.70)
egative predictive value; AUC, area under curve; CI, confidence
Figure 1 Receiver operating characteristic (ROC) curves of the bronchoalveolar lavage fluid (BALF) CD103þCD4þ/CD4þ and
CD103þCD4þ/CD103þCD8þ ratios in sarcoidosis patients independently of CD4þ/CD8þ ratio (a, c) and for those with a CD4þ/CD8þ
ratio <3.5 (b, d), respectively.
1018 P.C. Mota et al.In this context, the integrin CD103, expressed on intra-
epithelial lymphocytes in mucosal areas, such as bronchi,
has been studied in the diagnostic work-up of sarcoidosis. It
has been shown that the relative amount of CD103-
expressing T-cells in BALF differs in patients with ILD.
This variation is predominantly seen in the CD4þ T-cell
population, as most of the CD8þ T-cells express this integrin
independently of the type of disease.18 This was also shown
in our study, as a low expression of CD103þ was seen
on CD4þ rather than on CD8þ BALF T-lymphocytes.Subsequently, a significantly lower BALF CD103þCD4þ/CD4þ
ratio was also found in this group of patients. As other have
suggested, this is corroborative with the concept that, for
instance, lymphocytosis in HP results from the local
expansion of mucosal lymphocytes, while in sarcoidosis, is
the result of lymphocytes of non-mucosal origin. In fact,
the relative absence of CD103 on CD4þ BALF T-lymphocytes
is consistent with a peripheral origin of these cells, favoring
the hypothesis of redistribution from the peripheral blood
and compartmentalization into the lung.14,20,31,32 In fact, in
Table 4 Cutoff values, sensitivity (Sn), specificity (Sp), positive predictive value (PPV) and negative predictive value (NPV) for
different bronchoalveolar lavage fluid (BALF) criteria evaluated for sarcoidosis diagnosis for patients with BALF CD4þ/CD8þ ratio
<3.5 (n Z 12; 29.3%).
Criteria Selected cutoff Sn (%) Sp (%) PPV (%) NPV (%) AUC (CI 95%)
CD103þCD4þ (cells/mL) 2951 50 84 46 86 0.69 (0.53e0.85)
CD103þCD4þ (%) 18.85 75 76 45 92 0.74 (0.57e0.91)
CD103þCD4þ/CD4þ 0.45 75 78 47 92 0.79 (0.64e0.93)
CD103þCD8þ (cells/mL) 16,856 100 64 43 100 0.77 (0.65e0.89)
CD103þCD8þ (%) 27.65 50 82 43 86 0.64 (0.46e0.82)
CD103þCD8þ/CD8þ 1.65 50 69 30 84 0.48 (0.29e0.68)
CD103þCD4þ/CD103þCD8þ 0.45 58 73 37 87 0.60 (0.39e0.80)
Sn, sensitivity; Sp, specificity; PPV, positive predictive value (PPV); NPV, negative predictive value; AUC, area under curve; CI, confi-
dence interval.
CD103 expression in sarcoidosis 1019our study BALF CD103 expression adequately differentiated
sarcoidosis from the HP group, that showed a clearly higher
BALF CD103þCD4þ/CD4þ ratio (data not shown).
Our results support the relevance to evaluate CD103
expression in BALF CD4þ T-lymphocytes in sarcoidosis.
Independently of the CD4þ/CD8þ ratio, the BALF
CD103þCD4þ/CD4þ ratio for a cutoff of 0.25 presented
a high specificity (91%) for sarcoidosis diagnosis (Table 2). In
order to characterize the diagnostic performance of this
ratio, and to calculate the best relationship between
sensitivity and specificity, we determined the cutoff value
associated with the highest AUC value for this ratio, and for
other CD103 expression values. In fact, the CD103þCD4þ/
CD4þ ratio, for the cutoff 0.45, presented the highest AUC
value, with a sensitivity and specificity of 81% and 78%,
respectively. Taking into account these results, one can
speculate that the CD103þCD4þ/CD4þ ratio ranging from
0.25 to 0.45 can be a useful tool for sarcoidosis diagnosis
(Annex 1).
The potential diagnostic role of CD103 in sarcoidosis has
been previously demonstrated by some authors. We cannot
perform a direct comparison between our results and those
found by these groups, as methodologies used differed.
Kolopp-Sarda et al. have found that the combined use of
the CD4þ/CD8þ (2.5) and the CD103þ/CD4þ ratio (<0.31)
seems to be a promising new tool for sarcoidosis diagnosis,
with sensitivity around 96%.14 On the other hand, Heron
et al. have already demonstrated, in a total of 119 patients
with alveolar lymphocytosis (56 with pulmonary sarcoid-
osis), that the combined use of the CD103þCD4þ/CD4þ ratio
(cutoff <0.2) with the CD4þ/CD8þ (cutoff >3.0), or with
the relative alveolitis CD4þ/CD8þ BAL/periphery blood
ratio (cutoff >2.0), provides a specific tool for discrimi-
nating sarcoidosis from other ILD (sensitivity: 66%; speci-
ficity: 89%; PPV: 82%; NPV: 74%).20 As opposed to the
aforementioned study, this last work, performed by the
Dutch BAL working party, has some advantages, such as the
inclusion of sarcoidosis patients with a CD4þ/CD8þ <2.5,
revealing the additional usefulness of CD103 in those
patients without an apparent high CD4þ alveolitis. More-
over, the application of the CD103þCD4þ/CD4þ ratio rather
than the CD103þ/CD4þ ratio, prevents the misleading
effect of CD8þ lymphocytes, that co-express CD103 in most
lung diseases. Similarly, we did not evaluate CD103 global
expression and we included patients with a great variability
of BALF CD4þ/CD8þ ratio. Among our 41 sarcoidosispatients, 12 presented a CD4þ/CD8þ <3.5 (including 4
patients with an inverted CD4þ/CD8þ <1). In this subgroup
of patients, the CD103þCD4þ/CD4þ ratio for the same
cutoff point (0.45), as it was established for the total
sample, revealed a similar diagnostic performance, with an
expected higher negative predictive value (92%). This
emphasizes the potential diagnostic role of this ratio also in
sarcoidosis patients with a normal or inverted CD4þ/CD8þ
ratio, obviating the need of more invasive diagnostic tools
in order to obtain a histological confirmation. Our sample
also differed in the diagnostic criteria applied for sarcoid-
osis, as we included not only patients with biopsy-proven
diagnosis (the unique criteria applied in the former
studies), but also, patients with a high CD4þ/CD8þ ratio in
the presence of a clinical/radiological picture typical of
this diagnosis without histological confirmation. Conse-
quently, we cannot compare the diagnostic values of CD4þ/
CD8þ ratio and CD103 expression for sarcoidosis, as inde-
pendent or combined markers, as others have shown.
Although this is a potential limitation of our study, we
currently should not subject patients with a typical clinical,
radiological and BALF features of sarcoidosis to invasive
tests, in order to obtain a histological confirmation.
Additionally, the small number of patients with BALF
CD4þ/CD8þ ratio <3.5 could be considered a potential
limitation of this study. Nevertheless, our results are in line
with those previously described by Heron et al.,20 con-
cerning the diagnostic value of CD103 expression even in
sarcoidosis patients with BALF CD4/CD8 ratio <3.5.
As described in the literature, higher values of the BALF
CD103þCD4þ/CD4þ ratio were found in more advanced
sarcoidosis radiographic stages.19,20 CD103þ cells are
involved in fibrogenic inflammation, as shown by an analysis
of single nucleotide polymorphisms spanning ITGAE, the
gene encoding the aE (CD103) unit, suggesting that the
genotypic analysis of this integrin may also be helpful in
assessing sarcoidosis risk and prognosis.17,33
In conclusion, assessment of CD103 expression in BALF
CD4þ lymphocytes may be a reliable tool for sarcoidosis
diagnosis, independently of CD4þ/CD8þ ratio, pointing out
the relevance of evaluating this marker on the ILD diag-
nostic work-up. In our study, through an extensive analysis
of sensitivity and specificity of various forms of its expres-
sion we were able to redefine a BALF CD103þCD4þ/CD4þ
lymphocyte ratio 0.45 as a good diagnostic marker for
sarcoidosis, even in cases with CD4þ/CD8þ ratio <3.5.
1020 P.C. Mota et al.Conflict of interest
The authors have no conflict of interest.Appendix A. Supplementary material
Supplementary material associated with this article can be
found, in the online version, at doi:10.1016/j.rmed.2012.
03.020.
References
1. Hillerdal G, No¨u E, Osterman K, Schmekel B. Sarcoidosis:
epidemiology and prognosis. A 15-year European study. Am Rev
Respir Dis 1984;130:29e32.
2. Henke CE, Henke G, Elveback LR, Beard CM, Ballard DJ,
Kurland LT. The epidemiology of sarcoidosis in Rochester,
Minnesota: a population-based study of incidence and survival.
Am J Epidemiol 1986;123:840e5.
3. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med
2007;357:2153e65.
4. Nureki S, Miyazaki E, Ando M, Ueno T, Fukami T, Kumamoto T,
et al. Circulating levels of both Th1 and Th2 chemokines are
elevated in patients with sarcoidosis. Respir Med 2008;102:
239e47.
5. Costabel U, Hunninghake GW. ATS/ERS/WASOG statement on
sarcoidosis. Sarcoidosis Statement Committee. American
Thoracic Society. European Respiratory Society. World Associ-
ation for Sarcoidosis and Other Granulomatous Disorders. Eur
Respir J 1999;14:735e7.
6. Baughman RP, Culver DA, Judson MA. A concise review of
pulmonary sarcoidosis. Am J Respir Crit Care Med 2011;183:
573e81.
7. Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM,
Harrison NK, et al. British Thoracic Society Interstitial Lung
Disease Guideline GroupBritish Thoracic Society Standards of
Care CommitteeThoracic Society of AustraliaNew Zealand
Thoracic SocietyIrish Thoracic Society. Interstitial lung disease
guideline: the British Thoracic Society in collaboration with the
Thoracic Society of Australia and New Zealand and the Irish
Thoracic Society. Thorax 2008;63(Suppl. 5):v1e58.
8. Costabel U, Zaiss AW, Guzman J. Sensitivity and specificity of
BAL findings in sarcoidosis. Sarcoidosis 1992;9(Suppl. 1):211e4.
9. Winterbauer RH, Lammert J, Selland M, Wu R, Corley D,
Springmeyer SC. Bronchoalveolar lavage cell populations in the
diagnosis of sarcoidosis. Chest 1993;104:352e61.
10. Reichenberger F, Kleiber B, Baschiera B, Bubendorf L,
Brutsche M, Dalquen P, et al. Bronchoalveolar lavage quality
influences the T4/T8 ratio in sarcoidosis. Respir Med 2007;101:
2025e30.
11. Thomeer M, Demedts M. Predictive value of CD4/CD8 ratio in
bronchoalveolar lavage in the diagnosis of sarcoidosis. Sarcoid-
osis Vasc Diffuse Lung Dis 1997;14(Suppl. 1):36 (Abstract).
12. Costabel U. CD4/CD8 ratios in bronchoalveolar lavage fluid: of
value for diagnosing sarcoidosis? Eur Respir J 1997;10:2699e700.
13. Kantrow SP, Meyer KC, Kidd P, Raghu G. The CD4/CD8 ratio in
BAL fluid is highly variable in sarcoidosis. Eur Respir J 1997;10:
2716e21.
14. Kolopp-Sarda MN, Kohler C, De March AK, Be´ne´ MC, Faure G.
Discriminative immunophenotype of bronchoalveolar lavage
CD4 lymphocytes in sarcoidosis. Lab Invest 2000;80:1065e9.15. Kilshaw PJ. Alpha E beta 7. Mol Pathol 1999;52:203e7.
16. Erle DJ, Pabst R. Intraepithelial lymphocytes in the lung:
a neglected lymphocyte population. Am J Respir Cell Mol Biol
2000;22:398e400.
17. Braun RK, Foerster M, Grahmann PR, Haefner D,
Workalemahu G, Kroegel C. Phenotypic and molecular char-
acterization of CD103þCD4þ T cells in bronchoalveolar lavage
from patients with interstitial lung diseases. Cytometry B Clin
Cytom 2003;54:19e27.
18. Rihs S, Walker C, Virchow Jr JC, Boer C, Kroegel C, Giri SN,
et al. Differential expression of alpha E beta 7 integrins on
bronchoalveolar lavage T lymphocyte subsets: regulation by
alpha 4 beta 1-integrin crosslinking and TGF-beta. Am J Respir
Cell Mol Biol 1996;15:600e10.
19. Lohmeyer J, Friedrich J, Grimminger F, Maus U, Tenter R,
Morr H, et al. Expression of mucosa-related integrin alphaE-
beta7 on alveolar T cells in interstitial lung diseases. Clin Exp
Immunol 1999;116:340e6.
20. Heron M, Slieker WA, Zanen P, van Lochem EG, Hooijkaas H,
van den Bosch JM, et al. Evaluation of CD103 as a cellular
marker for the diagnosis of pulmonary sarcoidosis. Clin
Immunol 2008;126:338e44.
21. Kirks DR, McCormick VD, Greenspan RH. Pulmonary sarcoidosis.
Roentgenologic analysis of 150 patients. Am J Roentgenol
Radium Ther Nucl Med 1973;117:777e86.
22. Schuyler M, Cormier Y. The diagnosis of hypersensitivity
pneumonitis. Chest 1997;111:534e6.
23. American Thoracic Society/European Respiratory Society.
International multidisciplinary consensus classification of the
idiopathic interstitial pneumonias. Am J Respir Crit Care Med
2002;165:277e304.
24. Hochberg MC. Updating the American College of Rheumatology
revised criteria for the classification of systemic lupus eryth-
ematosus. Arthritis Rheum 1997;40:1725.
25. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF,
Cooper NS, et al. The American Rheumatism Association 1987
revised criteria for the classification of rheumatoid arthritis.
Arthritis Rheum 1988;31:315e24.
26. Preliminary criteria for the classification of systemic sclerosis
(scleroderma). Subcommittee for scleroderma criteria of the
American Rheumatism Association Diagnostic and Therapeutic
Criteria Committee. Arthritis Rheum 1980;23:581e90.
27. http://www.pneumotox.com/.
28. Adverse effects of crystalline silica exposure. American
Thoracic Society Committee of the Scientific Assembly on
Environmental and Occupational Health. Am J Respir Crit Care
Med 1997;155:761e8.
29. Technical recommendations and guidelines for bronchoalveo-
lar lavage (BAL). Report of the European Society of Pneumol-
ogy Task Group. Eur Respir J 1989;2:561e85.
30. Agostini C, Chilosi M, Zambello R, Trentin L, Semenzato G.
Pulmonary immune cells in health and disease: lymphocytes.
Eur Respir J 1993;6:1378e401.
31. Semenzato G. Immunology of interstitial lung diseases: cellular
events taking place in the lung of sarcoidosis, hypersensitivity
pneumonitis and HIV infection. Eur Respir J 1991;4:94e102.
32. Chailleux E, Bignon JD, Peyrat MA, Godard A, Soulillou JP.
Lymphocyte subsets, phytohaemagglutinin responsiveness of
blood lymphocytes, and interleukin 2 production in sarcoidosis.
Thorax 1985;40:768e73.
33. Heron M, Grutters JC, Van Moorsel CH, Ruven HJ, Kazemier KM,
Claessen AM, et al. Effect of variation in ITGAE on risk of
sarcoidosis, CD103 expression, and chest radiography. Clin
Immunol 2009;133:117e25.
